Spectrum Pharmaceuticals announces submission to FDA of updated BLA for ROLONTIS
The BLA for ROLONTIS is supported by data from two identically designed Phase 3 clinical trials, ADVANCE and RECOVER, which evaluated the safety and efficacy of ROLONTIS in